Recurrence of Cerebral Arteriovenous Malformation Following Complete Obliteration Through Endovascular Embolization

Hao, Qiang; Zhang, Haibin; Han, Heze; Jin, Hengwei; Ma, Li; Li, Ruinan; Li, Zhipeng; Li, Anqi; Yuan, Kexin; Zhu, Qinghui; Wang, Ke; Li, Runting; Lin, Fa; Wang, Chengzhuo; Zhang, Yukun; Zhang, Hongwei; Zhao, Yang; Jin, Weitao; Gao, Dezhi; Guo, Geng; Yan, Debin; Pu, Jun; Kang, Shuai; Ye, Xun; Li, Youxiang; Sun, Shibin; Wang, Hao; Chen, Yu; Chen, Xiaolin; Zhao, Yuanli; ,

doi:10.1007/s12975-023-01215-8

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Preprint1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The difference of functional MR imaging in evaluating outcome of patients with diffuse and compact brain arteriovenous malformation

Wen,

Zheng,

Guo

et al. 2024

Neurosurg Rev

View full text Add to dashboard Cite

The difference of functional MR imaging in evaluating outcome of patients with diffuse and compact brain arteriovenous malformation

Wen,

Zheng,

Guo

et al. 2024

Neurosurg Rev

View full text Add to dashboard Cite

Evaluation of AAV Capsids and Delivery Approaches for Hereditary Hemorrhagic Telangiectasia Gene Therapy

Yadav,

Liang,

Press

et al. 2024

Transl. Stroke Res.

View full text Add to dashboard Cite

Evaluation of Aav Capsids and Delivery Approaches for Hereditary Hemorrhagic Telangiectasia Gene Therapy

Yadav,

Liang,

Press

et al. 2024

Preprint

View full text Add to dashboard Cite

Nosebleeds and intracranial hemorrhage from brain arteriovenous malformations (bAVMs) are among the most devastating symptoms of patients with hereditary hemorrhagic telangiectasis (HHT). All available managements have limitations. We showed that intravenous delivery of soluble FMS-related tyrosine kinase 1 using an adeno-associated viral vector (AAV9-sFLT1) reduced bAVM severity of endoglin deficient mice. However, minor liver inflammation and growth arrest in young mice were observed. To identify AAV variants and delivery methods that can best transduce brain and nasal tissue with an optimal transduction profile, we compared 3 engineered AAV capsids (AAV.cc47, AAV.cc84 and AAV1RX) with AAV9. A single-stranded CBA promoter driven tdTomato transgene was packaged in these capsids and delivered intravenously (i.v.) or intranasally (i.n.) to wild-type mice. A CMV promoter driven Alk1 transgene was packaged into AAV.cc84 and delivered to PdgfbiCre;Alk1f/f mice through i.v. injection followed by brain AVM induction. Transduced cells in different organs, vessel density and abnormal vessels in the bAVMs, and liver inflammation were analyzed histologically. Liver and kidney function were measured enzymatically. Compared to other viral vectors, AAV.cc84, after i.v. delivery, transduced a high percentage of brain ECs and few hepatocytes; whereas after i.n. delivery, AAV.cc84 transduced ECs and perivascular cells in the brain, and ECs, epithelial cells, and skeletal muscles in the nose with minimum hepatocyte transduction. No changes to liver or kidney function were detected. Delivery of AAV.cc84-Alk1 through i.v. to PdgfbiCre;Alk1f/f mice reduced bAVM severity. In summary, we propose that AAV.cc84-Alk1 is a promising candidate for developing gene therapy in HHT patients.

show abstract

Recurrence of Cerebral Arteriovenous Malformation Following Complete Obliteration Through Endovascular Embolization

Cited by 3 publications

References 34 publications

The difference of functional MR imaging in evaluating outcome of patients with diffuse and compact brain arteriovenous malformation

The difference of functional MR imaging in evaluating outcome of patients with diffuse and compact brain arteriovenous malformation

Evaluation of AAV Capsids and Delivery Approaches for Hereditary Hemorrhagic Telangiectasia Gene Therapy

Evaluation of Aav Capsids and Delivery Approaches for Hereditary Hemorrhagic Telangiectasia Gene Therapy

Contact Info

Product

Resources

About